The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism- driven quantum mechanics and molecular dynamics simulations to calculate Active Pharmaceutical Ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection and formulation design. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets with high therapeutic potential that could benefit from its data-driven platform.
Location: United States, Massachusetts, Cambridge
Member count: 11-50
Investors 1
| Date | Name | Website |
| 10.04.2022 | IMO Ventur... | imo.vc/ |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 06.04.2022 | METiS Ther... | METiS Therapeutics, a firm foc... | - | - | pandaily.c... |